Regarding your point 6
"6. You make a comparison of Keytruda with PD1-Vaxx in the treatment of NSCLC !!! Do we have any data that will allow us to compare PD1-Vaxx vs Keytruda in mismatch repair-deficient /microsatellite instability high (dMMR/MSI-high) colorectal cancer ? I suspect not but I'm happy to see the evidence."
Quite timely that question of yours, here is a clip from LC today, making the following statement regarding neoPOLEM:
"So that's a very special study where other anti-PD-1's like ours, our PD1-VAXX also inhibits PD-1, where they've seen lots of activity from other companies... especially in this particular colorectal cancer..."
https://youtu.be/i0Il1gUDTCs?si=QXBwN9ZsXhFG1iYz&t=223
I know your time is so incredibly valuable, just thought you might be interested in this development - no need to respond.
- Forums
- ASX - By Stock
- Ann: 1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial
IMU
imugene limited
Add to My Watchlist
6.67%
!
1.4¢

Regarding your point 6 "6. You make a comparison of Keytruda...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.4¢ |
Change
-0.001(6.67%) |
Mkt cap ! $104.5M |
Open | High | Low | Value | Volume |
1.5¢ | 1.5¢ | 1.4¢ | $80.66K | 5.641M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
78 | 18420098 | 1.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.5¢ | 8992975 | 37 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
78 | 18420098 | 0.014 |
45 | 14382526 | 0.013 |
44 | 8640710 | 0.012 |
13 | 3085728 | 0.011 |
32 | 6300300 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 8992975 | 37 |
0.016 | 9758996 | 33 |
0.017 | 8455154 | 16 |
0.018 | 6121148 | 29 |
0.019 | 5429697 | 17 |
Last trade - 13.48pm 16/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |